Dataset Information


Stereotactic radiotherapy boost after definite chemoradiation for non-responding locally advanced NSCLC based on early response monitoring 18F-FDG-PET/CT.


Background and purpose

Prognosis of locally advanced non-small cell lung cancer remains poor despite chemoradiation. This planning study evaluated a stereotactic boost after concurrent chemoradiotherapy (30?×?2?Gy) to improve local control. The maximum achievable boost directed to radioresistant primary tumor subvolumes based on pre-treatment fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG-PET/CT) (pre-treatment-PET) and on early response monitoring 18F-FDG-PET/CT (ERM-PET) was compared.

Materials and methods

For ten patients, a stereotactic boost (VMAT) was planned on ERM-PET (PTVboost;ERM) and on pre-treatment-PET (PTVboost;pre-treatment), using a 70% SUVmax threshold with 7?mm margin to segmentate radioresistant subvolumes. Dose was escalated till organ at risk (OAR) constraints were met, aiming to plan at least 18?Gy in 3 fractions (EQD2 84?Gy/BED 100.8?Gy).


In five patients, PTVboost;ERM was 9-40% smaller relative to PTVboost;pre-treatment. Overlap of PTVboost;ERM with OARs decreased also compared to overlap of PTVboost;pre-treatment with OARs. However, any overlap with OAR remained in 4/5 patients resulting in minimal differences between planned dose before and during treatment. Median dose (EQD2) covering 99% and 95% of PTVboost;ERM were 15?Gy and 18?Gy respectively. Median boost volume receiving a physical dose of? ??18?Gy (V18) was 88%. V18 was???80% for PTVboost in six patients.


A significant stereotactic boost to volumes with high initial or persistent 18F-FDG-uptake could be planned above 60?Gy chemoradiation. Differences between planned dose before and during treatment were minimal. However, as an ERM-PET also monitors changes in tumor position, we recommend to plan the boost on the ERM-PET.

PROVIDER: S-EPMC7807537 | BioStudies |

REPOSITORIES: biostudies

Similar Datasets

| S-EPMC8237456 | BioStudies
| S-EPMC7807871 | BioStudies
| S-EPMC7732969 | BioStudies
| S-EPMC8161822 | BioStudies
| S-EPMC5546910 | BioStudies
| S-EPMC7807641 | BioStudies
2010-01-01 | S-EPMC2858110 | BioStudies
| S-EPMC8456416 | BioStudies
| S-EPMC8233460 | BioStudies
| S-EPMC6199734 | BioStudies